Evidence map›Paper›PMID 41811824›Full record

ArticlePloS one2026

Long non-coding RNA PSMB8-AS1 as a potential biomarker for postoperative recurrence in patients with Fuhrman grades 1-3 clear cell renal cell carcinoma.

Chieko Baba, Hiroshi Hirata, Koichiro Hiyoshi, Takanori Tokunaga, Nakanori Fujii, Kosuke Shimizu, Keita Kobayashi, Takahide Hayano, Yoshiyuki Asai, Koji Shiraishi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chieko BabaDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
Hiroshi HirataDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.ORCID https://orcid.org/0009-0004-1063-8646
Koichiro HiyoshiDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
Takanori TokunagaDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
Nakanori FujiiDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
Kosuke ShimizuDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
Keita KobayashiDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
Takahide HayanoDepartment of Systems Bioinformatics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.ORCID https://orcid.org/0000-0001-8454-3528
Yoshiyuki AsaiDepartment of Systems Bioinformatics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.
Koji ShiraishiDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) are important regulators of oncogenesis. In this study, we investigated the tumor-promoting role and prognostic value of the lncRNA PSMB8-AS1 in renal cell carcinoma (RCC). Using lncRNA microarray analysis, we identified PSMB8-AS1 as a candidate gene associated with disease progression and immune checkpoint inhibitor resistance. We examined PSMB8-AS1 expression in tumors and adjacent normal renal tissues from 192 patients with RCC. In vitro functional assays were performed to assess their role in cell proliferation and invasion. We also conducted bioinformatics and luciferase reporter assays to clarify the interaction between miR-204-5p/miR-211 and the transcription factor TFAP2A. PSMB8-AS1 was significantly overexpressed in clear cell RCC (ccRCC) tissues and correlated with poor prognosis. Knockdown experiments revealed that PSMB8-AS1 promoted proliferation and invasion. Mechanistically, PSMB8-AS1 functions as a competing endogenous RNA, sponging miR-204-5p/miR-211 and enhancing TFAP2A expression. These findings suggest that PSMB8-AS1 represents a promising biomarker for postoperative ccRCC recurrence.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellKidney NeoplasmsNeoplasm Recurrence, LocalRNA, Long NoncodingCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMicroRNAsMiddle AgedNeoplasm GradingPrognosisRNA, Competitive EndogenousBiomarkers, TumorMicroRNAsMIR204, humanRNA, Competitive EndogenousRNA, Long NoncodingTFAP2A protein, humanTranscription Factor AP-2

Identifiers

PMID41811824
PMCPMC12978458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.